Johnson & Johnson and 4 Other Biopharmaceutical Stocks That Might Be Ready to Break Out
Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...
Wells Fargo Reaffirms Their Buy Rating on Gilead Sciences (GILD)
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.
Bank of America Securities Remains a Buy on Gilead Sciences (GILD)
In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...
Oppenheimer Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price
Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report released on Tuesday, Marketbeat reports. Oppenheimer currently has an ...
Med Device Online15h
Lessons Learned From Vivani Medical's Study Of GLP-1 Implant
Vivani Medical Cofounder and CEO Adam Mendelsohn, Ph.D. discusses the company’s first application of the NanoPortal, ...
Shaping the future of healthcare analytics: Nidhi Shashikumar's data-driven Impact
With over seven years of experience in data science and analytics, Nidhi has led high-impact projects at leading healthcare ...